Asco 2020 virtual
ir.tizianalifesciences.com
The American Society of Clinical Oncology (ASCO) Virtual Conference will be held from May 29-31, 2020. In addition, the Company will publish online two e-abstracts featuring its Miliciclib compound for the treatment of hepatocellular carcinoma on 13 May 2020 but …
Investor Relations — Kura Oncology, Inc.
The Company is presenting these data at the American Society of Clinical Oncology (“ASCO”) Virtual Scientific Program being held May 29-31, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
CytomX Therapeutics, Inc.
ASCO 2020 PRESENTATIONS TO HIGHLIGHT MULTIPLE PROBODY CLINICAL-STAGE PROGRAMS. ... (ASCO) ASCO20 Virtual Scientific Program. CytomX and its partner AbbVie will present data from Phase 1 dose escalation study of the PROCLAIM-CX-2029 Phase 1/2 study of the anti CD71 Probody CX-2029.
AVEO Oncology
A copy of the poster will be available at the ASCO virtual meeting beginning today, May 29, 2020, at 8:00 AM ET. The poster and accompanying oral presentation by Sumanta (Monty) Pal, MD, Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research, and Co-director, Kidney Cancer Program, at City of Hope Comprehensive ...
Harpoon Therapeutics | Harpoon Therapeutics, Inc.
Harpoon plans to present interim HPN424 data at the ASCO 2020 Virtual Meeting (Abstract 5552). The Company will host a virtual event to provide a clinical trial and pipeline update in parallel with the ASCO meeting. Anticipated 2020 Milestones. HPN424
Stockholder Overview | Corvus Pharmaceuticals
As noted above, the Company will present updated data covering ciforadenant and the Adenosine Gene Signature in RCC at the 2020 ASCO Virtual Annual Meeting in May 2020. The Company plans to meet with U.S. Food & Drug Administration (FDA) to discuss the study design and plans for a ciforadenant pivotal study in advanced refractory RCC using the ...
Galera Therapeutics - Investor Relations
In May, presented new data at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which demonstrated statistically significant reductions by avasopasem on markers of chronic kidney disease due to concurrent cisplatin chemoradiation in a retrospective.
TRACON Pharmaceuticals Inc
On May 14, 2020, the Company issued a press release announcing the presentation of positive clinical data for envafolimab at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program by the Company’s partners 3D Medicines and Alphamab.
NantHealth
In June, announced the publication of four abstracts in the developmental therapeutics session of the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. In collaboration with ImmunityBio, LLC, the company presented data, gathered from its database, which was used to advance findings in molecularly targeted agents and ...
Oncternal Therapeutics, Inc.
The data will be presented as part of the American Society of Clinical Oncology (“ASCO”) 2020 Virtual Annual Meeting on May 29, 2020. As of the data cut-off date of April 30, 2020, 15 patients with relapsed/refractory MCL were enrolled in the dose-finding and dose-confirming cohorts of this clinical trial, 12 of whom were evaluable for ...
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Hot searches
- california attorney general nonprofit
- palo alto business plan pro premiere
- how long to charge a car battery
- american funds ica guide
- mgic mortgage insurance rate calculator
- loan to value ratio refinance
- free online exams tests
- google maps for laptops free download
- poorest cities in usa
- how to add an amendment to constitution